Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease

• Published in: Lipids in Health and Disease
• Main Authors: Tiansu Lv, Yan Lou, Qianhua Yan, Lijuan Nie, Zhe Cheng, Xiqiao Zhou
• Format: Article
• Language: English
• Published: BMC 2024-02-01
• Subjects: Phosphorylation; Steatotic liver disease; NAFLD; Pathogenesis
• Online Access: https://doi.org/10.1186/s12944-024-02037-9

Abstract Steatotic liver disease poses a serious threat to human health and has emerged as one of the most significant burdens of chronic liver disease worldwide. Currently, the research mechanism is not clear, and there is no specific targeted drug for direct treatment. Phosphorylation is widely regarded as the most common type of protein modification, closely linked to steatotic liver disease in previous studies. However, there is no systematic review to clarify the relationship and investigate from the perspective of phosphorylation. Phosphorylation has been found to mainly regulate molecule stability, affect localization, transform molecular function, and cooperate with other protein modifications. Among them, adenosine 5’-monophosphate-activated protein kinase (AMPK), serine/threonine kinase (AKT), and nuclear factor kappa-B (NF-kB) are considered the core mechanisms in steatotic liver disease. As to treatment, lifestyle changes, prescription drugs, and herbal ingredients can alleviate symptoms by influencing phosphorylation. It demonstrates the significant role of phosphorylation as a mechanism occurrence and a therapeutic target in steatotic liver disease, which could be a new star for future exploration.